Results 91 to 100 of about 40,495 (214)

Unraveling Suicidal Ideation and Behaviors in a Global Cohort of Individuals at Clinical High‐Risk for Psychosis: Multivariable Correlates and Subthreshold Psychotic Symptoms

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Suicidal ideation and behaviors (SIB) are common among individuals at clinical high risk for psychosis (CHR‐P), but their relationship with the overall clinical profile remains unclear. This study aimed to identify sociodemographic/clinical factors associated with SIB in CHR‐P individuals and to examine whether subthreshold ...
Stefano Damiani   +73 more
wiley   +1 more source

Optimizing psychosocial interventions in first-episode psychosis: current perspectives and future directions

open access: yesPsychology Research and Behavior Management, 2017
Nicholas JK Breitborde,1,2 Aubrey M Moe,1 Arielle Ered,3 Lauren M Ellman,3 Emily K Bell4 1Department of Psychiatry and Behavioral Health, 2Department of Psychology, The Ohio State University, Columbus, OH, 3Department of Psychology, Temple University ...
Breitborde NJK   +4 more
doaj  

Using the Danish Administrative Registers to Define Mental Disorders: Potential and Limitations of Using Different Data Sources

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Although the Danish health registers provide rich data for epidemiological mental health research, the comparability of findings is hindered by different definitions of mental disorders across studies. We aimed to describe different approaches taken by researchers to define mental disorders using Danish register data and quantify ...
Natalie C. Momen   +4 more
wiley   +1 more source

Cost‐Effectiveness of Early Dose Reduction or Discontinuation Versus Antipsychotic Maintenance After First‐Episode Psychosis: Results From the HAMLETT Study

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background After remission from a first episode psychosis (FEP), international clinical guidelines recommend continuation of antipsychotic medication for at least 1 year, although many patients wish to reduce or discontinue medication due to side effects or long‐term health concerns.
Frederick W. Thielen   +16 more
wiley   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

open access: yesAddiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens   +7 more
wiley   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

open access: yesAddiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

open access: yesAddiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer   +16 more
wiley   +1 more source

Unlocking ‘stuckness’ and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic‐assisted therapy for substance use and mental health problems

open access: yesAddiction, EarlyView.
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove   +3 more
wiley   +1 more source

Brain reward function in young people with cannabis use disorder: A functional magnetic resonance imaging study

open access: yesAddiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien   +15 more
wiley   +1 more source

Marketing features of derived intoxicating cannabinoid product brands on Instagram: A content analysis

open access: yesAddiction, EarlyView.
Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy